Copyright Reports & Markets. All rights reserved.

Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Teduglutide
      • 1.4.3 Linaclotide
      • 1.4.4 Others
    • 1.5 Market by Application
      • 1.5.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Share by Application (2014-2025)
      • 1.5.2 Hospital Pharmacies
      • 1.5.3 Retail Pharmacies
      • 1.5.4 Online Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Peptide Based Gastrointestinal Disorders Therapeutics Market Size
    • 2.2 Peptide Based Gastrointestinal Disorders Therapeutics Growth Trends by Regions
      • 2.2.1 Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Regions (2014-2025)
      • 2.2.2 Peptide Based Gastrointestinal Disorders Therapeutics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Manufacturers
      • 3.1.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players Head office and Area Served
    • 3.3 Key Players Peptide Based Gastrointestinal Disorders Therapeutics Product/Solution/Service
    • 3.4 Date of Enter into Peptide Based Gastrointestinal Disorders Therapeutics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type (2014-2019)
    • 4.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 5.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in United States
    • 5.3 United States Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 5.4 United States Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    6 Europe

    • 6.1 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 6.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in Europe
    • 6.3 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 6.4 Europe Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    7 China

    • 7.1 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 7.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in China
    • 7.3 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 7.4 China Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    8 Japan

    • 8.1 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 8.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in Japan
    • 8.3 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 8.4 Japan Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 9.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in Southeast Asia
    • 9.3 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 9.4 Southeast Asia Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    10 India

    • 10.1 India Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 10.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in India
    • 10.3 India Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 10.4 India Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Peptide Based Gastrointestinal Disorders Therapeutics Market Size (2014-2019)
    • 11.2 Peptide Based Gastrointestinal Disorders Therapeutics Key Players in Central & South America
    • 11.3 Central & South America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Type
    • 11.4 Central & South America Peptide Based Gastrointestinal Disorders Therapeutics Market Size by Application

    12 International Players Profiles

    • 12.1 Shire
      • 12.1.1 Shire Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Peptide Based Gastrointestinal Disorders Therapeutics Introduction
      • 12.1.4 Shire Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2014-2019)
      • 12.1.5 Shire Recent Development
    • 12.2 Ironwood Pharmaceuticals
      • 12.2.1 Ironwood Pharmaceuticals Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Peptide Based Gastrointestinal Disorders Therapeutics Introduction
      • 12.2.4 Ironwood Pharmaceuticals Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2014-2019)
      • 12.2.5 Ironwood Pharmaceuticals Recent Development
    • 12.3 Astellas Pharma
      • 12.3.1 Astellas Pharma Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Peptide Based Gastrointestinal Disorders Therapeutics Introduction
      • 12.3.4 Astellas Pharma Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2014-2019)
      • 12.3.5 Astellas Pharma Recent Development
    • 12.4 Allergan
      • 12.4.1 Allergan Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Peptide Based Gastrointestinal Disorders Therapeutics Introduction
      • 12.4.4 Allergan Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2014-2019)
      • 12.4.5 Allergan Recent Development
    • 12.5 Takeda Pharmaceutical
      • 12.5.1 Takeda Pharmaceutical Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Peptide Based Gastrointestinal Disorders Therapeutics Introduction
      • 12.5.4 Takeda Pharmaceutical Revenue in Peptide Based Gastrointestinal Disorders Therapeutics Business (2014-2019)
      • 12.5.5 Takeda Pharmaceutical Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Gastrointestinal disorders refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas.
      In 2018, the global Peptide Based Gastrointestinal Disorders Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Peptide Based Gastrointestinal Disorders Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Peptide Based Gastrointestinal Disorders Therapeutics development in United States, Europe and China.

      The key players covered in this study
      Shire
      Ironwood Pharmaceuticals
      Astellas Pharma
      Allergan
      Takeda Pharmaceutical
      ...

      Market segment by Type, the product can be split into
      Teduglutide
      Linaclotide
      Others

      Market segment by Application, split into
      Hospital Pharmacies
      Retail Pharmacies
      Online Pharmacies

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Peptide Based Gastrointestinal Disorders Therapeutics status, future forecast, growth opportunity, key market and key players.
      To present the Peptide Based Gastrointestinal Disorders Therapeutics development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Peptide Based Gastrointestinal Disorders Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now